Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.66 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7403206 | 0.98 | GBA1 (0.63) | GBA1EP300SLC6A4HRH3HRH4 | |
| SCHEMBL31276928 | 0.85 | GBA1 (0.43) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4245166 | 0.84 | GBA1 (0.66) | GBA1EP300SLC6A4HRH3HRH4 | |
| Hydrochloric Acid SCHEMBL7405599 | 0.82 | GBA1 (0.63) | GBA1EP300SLC6A4HRH3HRH4 | |
| SCHEMBL18617326 | 0.82 | GBA1 (0.62) | GBA1SLC6A4SLC6A2 | |
| SCHEMBL31276934 | 0.81 | GBA1 (0.41) | GBA1SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL31276957 | 0.81 | LTA4H (0.44) | GBA1SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL1034368 | 0.80 | GBA1 (0.56) | GBA1SLC6A4HRH3SLC6A2SLC6A3 | |
| SCHEMBL27535617 | 0.80 | GBA1 (0.56) | GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL578602 | 0.80 | GBA1 (0.66) | GBA1EP300SLC6A4HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | GBA1 2693/4885EP300 2034/4885SLC6A4 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.